Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status

被引:112
|
作者
Chen, Lu [1 ,2 ]
Li, Christopher I. [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
关键词
AFRICAN-AMERICAN WOMEN; HISPANIC WHITE WOMEN; SOCIOECONOMIC-STATUS; RACIAL/ETHNIC DIFFERENCES; SCREENING MAMMOGRAPHY; ETHNIC-DIFFERENCES; INSURANCE STATUS; SURVIVAL; BLACK; STAGE;
D O I
10.1158/1055-9965.EPI-15-0293
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: African American and Hispanic women are more likely to be diagnosed with aggressive forms of breast cancer. Disparities within each subtype of breast cancer have not been well documented. Methods: Using data from 18 SEER cancer registries, we identified 102,064 women aged 20 years or older, diagnosed with invasive breast cancer in 2010-2011, and with known stage, hormone receptor (HR), and HER2 status. Associations between race/ethnicity and cancer stage and receipt of guideline-concordant treatment were evaluated according to HR/HER2 status. Results: Overall, African American and Hispanic women were 30% to 60% more likely to be diagnosed with stage II-IV breast cancer compared with non-Hispanic whites. African American women had 40% to 70% higher risks of stage IV breast cancer across all four subtypes. American Indian/Alaska Native women had a 3.9-fold higher risk of stage IV triple-negative breast cancer. African American and Hispanic whites were 30% to 40% more likely to receive non-guideline-concordant treatment for breast cancer overall and across subtypes. Conclusions: Women in several racial/ethnic groups are more likely to be diagnosed with more advanced stage breast cancer. African American and American Indian/Alaska Native women in particular had the highest risk of being diagnosed with stage IV triple-negative breast cancer. African American and Hispanic women were also consistently at higher risk of not receiving guideline-concordant treatment across subtypes. Impact: These findings provide important characterization of which subtypes of breast cancer racial/ethnic disparities in stage and treatment persist. (C) 2015 AACR.
引用
收藏
页码:1666 / 1672
页数:7
相关论文
共 50 条
  • [1] Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey
    Kuzhan, A.
    Adli, M.
    Alkis, H. Eryigit
    Caglayan, D.
    JOURNAL OF BUON, 2013, 18 (03): : 619 - 622
  • [2] US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
    Howlader, Nadia
    Altekruse, Sean F.
    Li, Christopher I.
    Chen, Vivien W.
    Clarke, Christina A.
    Ries, Lynn A. G.
    Cronin, Kathleen A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05):
  • [3] Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe
    Gao, Sue
    Barber, Beth
    Schabert, Vernon
    Ferrufino, Cheryl
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (07) : 1111 - 1118
  • [4] Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status
    Stahl, Kelly
    Wong, William
    Dodge, Daleela
    Brooks, Ashton
    McLaughlin, Christopher
    Olecki, Elizabeth
    Lewcun, Joseph
    Newport, Kristina
    Vasekar, Monali
    Shen, Chan
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (05) : 2646 - 2658
  • [5] Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer
    Yilmaz, Mukaddes
    Erdis, Eda
    Ucar, Mahmut
    Demir, Necla
    Alandag, Celal
    Yucel, Birsen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (05) : 521 - 529
  • [6] HER2 status and disparities in luminal breast cancers
    Holowatyj, Andreana N.
    Ruterbusch, Julie J.
    Ratnam, Manohar
    Gorski, David H.
    Cote, Michele L.
    CANCER MEDICINE, 2016, 5 (08): : 2109 - 2116
  • [7] Racial, ethnic and socioeconomic disparities in diagnosis, treatment, and survival of patients with breast cancer
    Azin, Arash
    Tahmasebi, Houman
    Brar, Amanpreet
    Azin, Sam
    Ko, Gary
    Covelli, Andrea
    Cil, Tulin
    AMERICAN JOURNAL OF SURGERY, 2023, 225 (01) : 154 - 161
  • [8] Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer
    Baulies, S.
    Cusido, M.
    Gonzalez-Cao, M.
    Tresserra, F.
    Fargas, F.
    Rodriguez, I.
    Ubeda, B.
    Ara, C.
    Fabregas, R.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 35 (05) : 485 - 489
  • [9] Socioeconomic disparities and breast cancer hormone receptor status
    Abegail A. Andaya
    Lindsey Enewold
    Marie-Josèphe Horner
    Ismail Jatoi
    Craig D. Shriver
    Kangmin Zhu
    Cancer Causes & Control, 2012, 23 : 951 - 958
  • [10] Socioeconomic disparities and breast cancer hormone receptor status
    Andaya, Abegail A.
    Enewold, Lindsey
    Horner, Marie-Josephe
    Jatoi, Ismail
    Shriver, Craig D.
    Zhu, Kangmin
    CANCER CAUSES & CONTROL, 2012, 23 (06) : 951 - 958